Diabetes treatment tech company Bigfoot Biomedical announced today that it raised $55 million to close its Series C financing round. Abbott (NYSE:ABT) led the funding round with participation from new investor Smile Group and existing investors Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management. Get the full story at our sister site, MassDevice.
Canada orders 37 million syringes from BD in anticipation of COVID-19 vaccine
Canada reportedly signed a contract to purchase 37 million syringes from Becton Dickinson (NYSE:BDX) in preparation for a potential COVID-19 vaccine. A report in The Record revealed that Public Services & Procurement Minister Anita Anand said the country made a purchase order from the Canadian branch of BD in an effort to make sure Canada is ready for […]
Merck eyes tiny patches as a vaccine delivery method
Merck has exercised its option to use Vaxxas‘ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate, the companies announced today. The companies did not disclose what the vaccine candidate is supposed to treat. But Merck this month announced two COVID-19 vaccine development efforts: a collaboration with IAVI and plans […]
FDA clears Propeller Health sensor to work with Symbocort inhaler
Propeller Health announced that it received FDA 510(k) clearance for connecting patients using its Symbicort Inhaler to its digital health platform. The Madison, Wis.-based company’s digital health platform already connects to inhalers used by asthma and COPD patients, including ones manufactured by Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion, along with other generic equivalents. Get the full […]
Baxter wins CE Mark for EVO IQ syringe system
Baxter (NYSE:BAX) announced that it received regulatory approval in Europe and Australia for its Evo IQ syringe infusion system. With CE Mark approval in Europe and a nod from Australia’s Therapeutic Goods Administration (TGA), the company expects hospitals in the United Kingdom, Ireland, Greece, Australia and New Zealand to be among the first to receive the […]
Molex taps former Ecolab SVP to run its medical business, including Phillips-Medisize
Paul Chaffin — most recently SVP of enterprise initiatives at Ecolab — has become SVP in charge of Molex’s Medical and Pharmaceutical Solutions division, including contract manufacturing giant Phillips-Medisize. Chaffin will report to Molex CEO Joe Nelligan and will be a member of the company’s Global Leadership Team. Get the full story on our sister […]
Icon appoints new chief medical officer
Icon said it appointed Kristen Buck as chief medical officer. Prior to joining the company, Buck was senior VP and chief of clinical development at Optum Insights where she led the clinical operations and regulatory group. She has experience in multiple therapy areas, including GI, neuroscience, dermatology, ophthalmology, oncology, cardiovascular/metabolic, immunology, renal, women’s health, orphan […]
Kindeva Drug Delivery launches as independent company from 3M
Kindeva Drug Delivery recently announced that it launched as an independent company, shedding its former 3M Drug Delivery Systems name. The formation of the independent company follows its acquisition by Altaris Capital Partners in a transaction that was worth $650 million. Through the acquisition, 3M will hold a 17% minority interest in Kindeva with Altaris. […]
B. Braun lands FDA EUA for use of infusion pumps with nebulizers to treat COVID-19
B. Braun Medical announced that it received FDA emergency use authorization to use its infusion pumps with nebulizers to treat patients with COVID-19. The Bethlehem, Pa.-based company’s authorization win includes its Perfusor space syringe infusion pump, Infusomat space volumetric infusion pump and Outlook ES pump systems. The pumps can be used for tracheal delivery of continuous […]
FDA approves Cipla’s generic albuterol inhaler
The FDA approved the first generic version of the Proventil HFA (albuterol sulfate) metered-dose inhaler for treating bronchospasm. The FDA indicated the generic inhaler from Cipla for the treatment or prevention of bronchospasm in patients four years of age or older with reversible obstructive airway disease. It also aids in the prevention of exercise-induced bronchospasm […]
